Search

Author/Creator Hoque, Shamia

6. Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). (January 2021)

Authors:
Bennett, Charles L.; Hoque, Shamia; Olivieri, Nancy; Taylor, Matthew A.; Aboulafia, David; Lubaczewski, Courtney; Bennett, Andrew C.; Vemula, Jay; Schooley, Benjamin; Witherspoon, Bartlett J.; Godwin, Ashley C; Ray, Paul S.; Yarnold, Paul R.; Ausdenmoore, Henry C.; Fishman, Marc; Herring, Georgne...
Journal:
EClinicalMedicine
Issue:
Volume 31(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. End of an era for erythropoiesis‐stimulating agents in oncology. Issue 10 (28th February 2020)

Authors:
Schoen, Martin W.; Hoque, Shamia; Witherspoon, Bartlett J.; Schooley, Benjamin; Sartor, Oliver; Yang, Y. Tony; Yarnold, Paul R.; Knopf, Kevin B.; Hrushesky, William J.M.; Dickson, Michael; Chen, Brian J.; Nabhan, Chadi; Bennett, Charles L.
Journal:
International journal of cancer
Issue:
Volume 146:Issue 10(2020)
Page Start:
2829
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Issue 12 (December 2020)

Authors:
Bennett, Charles L; Schoen, Martin W; Hoque, Shamia; Witherspoon, Bartlett J; Aboulafia, David M; Hwang, Catherine S; Ray, Paul; Yarnold, Paul R; Chen, Brian K; Schooley, Benjamin; Taylor, Matthew A; Wyatt, Michael D; Hrushesky, William J; Yang, Y Tony
Journal:
Lancet oncology
Issue:
Volume 21:Issue 12(2020)
Page Start:
e575
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗